Compare Baker Hughes Co (BKR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Incyte Corporation — how do they compare? Baker Hughes Co trades at $64.74 (market cap $64.34B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Baker Hughes Co is far larger — about 2.6× Incyte Corporation's market cap, and Baker Hughes Co pays a 1.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BKR | INCY | |
|---|---|---|
Market Cap | $64.34B | $24.54B |
Sector | Energy | Health |
52-Week High | $69.67 | $129.93 |
52-Week Low | $42.51 | $81.61 |
Enterprise Value | $64.86B | $20.04B |
Dividend Yield | 1.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
